Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 11;12(1):38.
doi: 10.1186/s13045-019-0725-6.

Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

Zeinab Safarpour Lima  1 , Mostafa Ghadamzadeh  2 , Farzad Tahmasebi Arashloo  3 , Ghazaleh Amjad  1 , Mohammad Reza Ebadi  4 , Ladan Younesi  5
Affiliations
Review

Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

Zeinab Safarpour Lima et al. J Hematol Oncol. .

Abstract

Breast cancer is the most common malignancy in women all over the world. Genetic background of women contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase the risk of developing certain cancers and are responsible for many of the cancers that run in some families. Regarding the widespread multigene panels, whole exome sequencing is capable of providing the evaluation of genetic function mutations for development novel strategy in clinical trials. Targeting the mutant proteins involved in breast cancer can be an effective therapeutic approach for developing novel drugs. This systematic review discusses gene mutations linked to breast cancer, focusing on signaling pathways that are being targeted with investigational therapeutic strategies, where clinical trials could be potentially initiated in the future are being highlighted.

Keywords: Breast; Chromosome; Molecular patterns; Mutations; New drug.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Does not apply as it is a review article.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Yang JD, Lee JW, Kim WW, Jung JH, Park HY. Oncoplastic surgical techniques for personalized breast conserving surgery in breast cancer patient with small to moderate sized breast. J Breast Cancer. 2011;14(4):253–261. doi: 10.4048/jbc.2011.14.4.253. - DOI - PMC - PubMed
    1. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:747318. doi: 10.1155/2013/747318. - DOI - PMC - PubMed
    1. Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, et al. Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer. Hered Cancer Clin Pract. 2015;13(1):2. doi: 10.1186/s13053-014-0022-x. - DOI - PMC - PubMed
    1. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–822. doi: 10.1093/jnci/djt095. - DOI - PubMed
    1. Van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr) 2011;34:71–88. doi: 10.1007/s13402-011-0010-3. - DOI - PMC - PubMed